Skip to main content

Cytosorbents Corporation (CTSO) Stock Forecast

Data as of Sep 20, 2026

Healthcare · Current price $5.52 (-4.17%)

Consensus Target
Upside
Analysts
1
Rating
Buy(2.00)

Consensus Price Target Over Time

Analyst Rating Distribution

Last 3 Months

No ratings in the last 3 months.
Strong Buy0
Buy0
Hold0
Sell0
Strong Sell0

6-Month Trend

No rating trend data.

Latest Analyst Forecasts

Price targets issued by Wall Street analysts. Upside calculated against today's price.

No analyst price targets available.

CTSO vs Sector & Market

MetricCTSOHealthcare AvgLarge Cap Avg
Analyst Rating2.002.262.42
Analyst Count1818
Target Upside+22217.1%+21.5%
P/E Ratio-4.603.7738.34

Revenue Estimates

PeriodLowAvgHigh#
2026-12-31$40M$41M$41M2
2027-12-31$48M$49M$50M1
2028-12-31$56M$57M$58M2
2029-12-31$72M$73M$74M1
2030-12-31$131M$133M$135M1

EPS Estimates

PeriodLowAvgHigh#
2026-12-31$-0.23$-0.17$-0.102
2027-12-31$-0.06$-0.06$-0.061
2028-12-31$-0.04$0.01$0.072
2029-12-31$0.14$0.14$0.141
2030-12-31$0.57$0.58$0.591

Frequently Asked Questions

What is the analyst consensus for CTSO?

The consensus among 1 analysts covering Cytosorbents Corporation (CTSO) is Buy with an average price target of N/A.

How many analysts cover CTSO?

1 analysts have issued ratings for Cytosorbents Corporation in the past 12 months.

Is CTSO a buy or sell right now?

Based on 1 analyst ratings, CTSO has a consensus rating of Buy (2.00/5) with a N/A upside to the consensus target of N/A.

What are the earnings estimates for CTSO?

Analysts estimate CTSO will report EPS of $-0.17 for the period ending 2026-12-31, with revenue estimated at $41M.

Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.